For the past several years, success has grown more elusive for American biotech firms. Even in the more robust investment climates prior to 2022, developing and growing a biotech always required a combination of risk appetite and patient capital that did not lend itself to the rapid exits typical of other areas of tech investing. …
Novo Nordisk sues Hims for GLP-1 patent infringement
Imitation is the sincerest form of flattery, some say. Novo Nordisk would probably disagree. Copycats of the company’s popular weight loss treatment, Wegovy, have been popping up for years. One copycat comes from the company Hims & Hers, an online provider of obesity medications as well as erectile dysfunction and hair regrowth treatments. Hims &…
Moderna says Pfizer-BioNTech COVID vaccine infringed its patents
Moderna (Nasdaq:MRNA) announced today that it is suing Pfizer (NYSE:PFE) and its COVID-19 vaccine partner BioNTech (Nasdaq:BNTX) over patent infringement in U.S. and German courts. Cambridge, Massachusetts–based Moderna said it is in the process of filing the complaints in U.S. District Court in Massachusetts and the Regional Court of Düsseldorf in Germany. The suits could…
Pfizer accuses former employees of trade secret theft
Pfizer (NYSE:PFE) is suing Regor Therapeutics, a China-headquartered company that announced a $1.5 billion diabetes alliance with Eli Lilly (NYSE:LLY) in late 2021. Filed in the U.S. District Court for the District of Delaware, Pfizer’s lawsuit also accuses former employees Xiayang Qiu, Min Zhong and 10 unnamed individuals of using its trade secrets as the…
Answering the CDMO shortage: A new paradigm for drug development
What can the pharma industry do about the critical shortage of contract manufacturing organization (CMO) and contract development and manufacturing company (CDMO) facilities? For a growing number of young entrepreneurial drug companies, the answer is a middle ground between building their own facilities and outsourcing to the saturated CMO/CDMO market. This middle ground lies in…
Pharma researcher charged with theft of trade secrets
A former director of medical and scientific affairs at Merck (NYSE:MRK) faces criminal charges in federal court in New Jersey for allegedly stealing and transmitting trade secrets. Shafat A. Quadri has been released on $100,000 unsecured bond. He was most recently employed at AstraZeneca (NSDQ:AZN). The single count of trade secret theft carries a maximum potential…
What impact might a Biden administration have on drug patent law reform in China?
While the pharma industry sorts out what impact a Biden administration is likely to have on drug pricing, another consideration meaningful for the sector is the trade relations between China and the U.S. — and how they may affect drug patent law. As part of recent trade negotiations, Chinese authorities agreed to change their intellectual property…
Hackers targeted pharma and other IP for Chinese government, indictment claims
A federal grand jury in Spokane, Wash. has indicted two Chinese nationals on charges that they hacked into pharma companies and hundreds of other businesses, governments and organizations — in some cases on behalf of the Chinese Ministry of State Security. The 11-count indictment, which the U.S. Department of Justice announced today, alleges that Li…







